GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to fight stomach cancer in the abdomen
Disease control OngoingThis early-phase trial tests whether adding an immune-boosting drug (aldesleukin) to standard chemotherapy and another immunotherapy (nivolumab) can help control stomach cancer that has spread to the lining of the abdomen. About 15 adults with this advanced cancer will receive th…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
New combo therapy targets Hard-to-Treat stomach cancers in Mid-Stage trial
Disease control OngoingThis phase II trial is testing whether adding chemotherapy to the immunotherapy drug atezolizumab works better than atezolizumab alone for patients with a specific genetic type of stomach or gastroesophageal junction cancer (MSI-H/dMMR). The study involves 240 adults with localiz…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
Immunotherapy combo shows promise in esophageal cancer trial
Disease control TerminatedThis study looks at whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer before and after surgery. About 278 adults with stage II to IVA cancer will take part. The…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise in rare stomach cancer trial
Disease control OngoingThis phase 2 trial is testing whether adding the drug neratinib to a standard combination of chemotherapy, trastuzumab, and pembrolizumab can shrink tumors in people with HER2-positive gastroesophageal cancers. The study includes 8 participants and aims to measure how many respon…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo aims to outperform standard immunotherapy in stomach cancer
Disease control OngoingThis phase 3 study tests whether a new combination of two immunotherapy drugs (domvanalimab and zimberelimab) plus chemotherapy works better than the current standard (nivolumab plus chemotherapy) for people with advanced stomach, gastroesophageal junction, or esophageal cancer t…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for advanced stomach cancer: drug cocktails under trial
Disease control OngoingThis study tests whether combining new drugs with or without chemotherapy can safely control advanced stomach, GEJ, or esophageal cancer. About 332 adults with inoperable or metastatic disease will receive different treatment combinations. The goal is to find more effective optio…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for stomach cancer: targeted drug shows promise in Late-Stage trial
Disease control OngoingThis phase 3 trial compares a newer targeted drug, trastuzumab deruxtecan, against a standard combination of two other drugs (ramucirumab and paclitaxel) in 490 adults with HER2-positive stomach or gastro-esophageal junction cancer that has worsened after initial treatment with t…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New Antibody-Drug conjugate shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug aims to shrink hard-to-treat GI tumors
Disease control OngoingThis study tests a new medicine called raludotatug deruxtecan in about 160 adults with advanced gastrointestinal cancers (pancreatic, bile duct, gallbladder, colorectal, stomach, or gastroesophageal junction). The drug is designed to attach to cancer cells and deliver a treatment…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail shows promise against aggressive stomach cancer
Disease control OngoingThis study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and targeted therapy (trastuzumab) can better shrink HER2-positive stomach or gastroesophageal junction cancer before surgery. About 42 adults with advanced but removable tumors will rec…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New cocktail of drugs shows promise against stomach cancer in early trial
Disease control OngoingThis phase 2 trial tests whether a combination of lenvatinib, pembrolizumab, and chemotherapy (FLOT) can shrink stomach tumors before surgery and prevent recurrence afterward. It involves 43 adults with untreated, non-metastatic stomach cancer. The main goal is to see how many pa…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug cocktail shows promise in shrinking HER2+ stomach tumors before surgery
Disease control OngoingThis phase 2 study tests two approaches for HER2-positive stomach or gastroesophageal junction cancer that hasn't spread. One group gets trastuzumab deruxtecan alone before surgery. Another group gets a combination of trastuzumab deruxtecan, capecitabine, and durvalumab both befo…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New mRNA vaccine shows promise in fighting solid tumors
Disease control OngoingThis early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for stomach cancer: phase 3 trial of MK-2870 launches
Disease control OngoingThis phase 3 trial compares a new drug, MK-2870, against standard treatments for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has spread and not responded to prior therapies. About 450 participants will be randomly assigned to receive either …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for advanced stomach cancer: experimental drug LM-302 enters final testing phase
Disease control OngoingThis study tests an experimental drug called LM-302 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after at least two prior therapies. The trial includes 387 adults whose tumors have a specific protein (CLDN1…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: LaNova Medicines Zhejiang Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Stomach cancer trial combines Belly-Infused chemo with standard drugs
Disease control OngoingThis phase II trial tests a combination of chemotherapy drugs for stomach cancer that has spread to the lining of the abdomen. About 40 adults will receive standard intravenous chemo plus paclitaxel infused directly into the abdomen. The goal is to see if this approach improves h…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for stomach cancer: targeted combo therapy enters final trial phase
Disease control OngoingThis study tests a new drug called ASKB589 combined with chemotherapy and an immunotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread. The trial includes 780 participants whose tumors have a specific marker (CLDN18.2). The goal is to see …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug trial hopes to shrink Hard-to-Treat tumors
Disease control OngoingThis early-stage study tests a new drug, TORL-2-307-ADC, in 163 people with advanced solid tumors like stomach, pancreas, or esophageal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have measurable disease and be well enough for …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New targeted combo shows promise for tough stomach cancer
Disease control OngoingThis clinical trial is testing whether adding a targeted drug called bemarituzumab to standard chemotherapy and immunotherapy (nivolumab) helps people with advanced stomach or gastroesophageal junction cancer live longer. The study includes 515 adults whose tumors overexpress a p…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New Dual-Action antibody takes on advanced cancers
Disease control OngoingThis early-phase study tests a new drug called SI-B003 in 60 people with advanced solid tumors that have spread or come back. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to find a safe dose and check for side effect…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New cocktail targets Hard-to-Treat stomach cancer
Disease control OngoingThis early-stage trial is testing a new drug called ASKB589, which targets a protein (CLDN18.2) found on some stomach cancer cells. It is given together with standard chemotherapy and an immunotherapy drug. The study includes 62 people with advanced stomach or gastroesophageal ju…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated Jun 26, 2026 16:04 UTC
-
New drug ASKB589 tested against advanced cancers
Disease control OngoingThis study tests an experimental drug called ASKB589 in about 199 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. People with stomach or pancreatic cancer are especially wanted for …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:35 UTC
-
New drug combo shows promise for tough esophageal cancer
Disease control OngoingThis study tests adding the immunotherapy drug durvalumab to standard chemoradiation for people with esophageal or gastroesophageal junction cancer. About 64 participants will receive the combination to see if it is safe and effective. The goal is to improve cancer control withou…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 13:41 UTC
-
Heated chemo during surgery may stop stomach Cancer's return
Prevention ENROLLING_BY_INVITATIONThis study tests whether giving heated chemotherapy directly into the abdomen during surgery can prevent stomach or gastroesophageal junction cancer from returning in the abdominal lining. The treatment uses drugs cisplatin and paclitaxel, which are heated and circulated in the b…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Jul 02, 2026 02:00 UTC
-
Virtual diet coaching aims to boost nutrition after stomach cancer surgery
Symptom relief OngoingThis study tests a telehealth program designed to help people improve their diet and quality of life after surgery for stomach or esophagus cancer. About 53 patients who have had curative surgery will receive virtual sessions with diet support. The goal is to see if the program i…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Scientists dig into past cases to find best brain tumor treatments for stomach cancer patients
Knowledge-focused OngoingThis study reviews medical records from 230 adults with stomach or esophagus cancer that spread to the brain. Researchers want to see which local treatments (like surgery or radiation) worked best and how long patients lived. The goal is to gather information to help doctors make…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Blokhin's Russian Cancer Research Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC